- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00261131
Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy
Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study proposes to: (1) to determine if injections of BTX-A to the hamstring muscles result in measurable physiologic (body structure and body function) changes not observed with normal saline injections, in children with spastic diplegic CP who walk with a flexed-knee gait pattern; (2) to assess whether physiologic changes translate into functional (activity and participation) improvements; (3) to evaluate family's perception of change in function, activity, participation, and quality of life.
This study will demonstrate if BTX-A injected into overactive hamstring muscles of children with spastic cerebral palsy (CP) and a flexed-knee walking pattern has measurable effects across the spectrum of dimensions of disablement of the International Classification of Functioning, Disability, and Health (ICF). It is a multi-center, prospective, randomized, double-blind trial comparing results of injection of BTX- A and placebo saline in controls, into overactive hamstring muscles, using multiple outcomes measures. Temporal-spatial gait parameters, instrumented 3DGA kinematics, passive ROM, spasticity measurement with both Ashworth and Tardieu scales, muscle strength/control, Gross Motor Function Measurement (GMFM), Pediatric Outcomes Data Collection Instrument (PODCI), Gillette Functional Assessment Questionnaire (FAQ), 6-Minute Walk Test, and Goal Attainment Scale (GAS), assessing all ICF domains, will be collected at baseline and at 1 month, 3 months, and 6 months post-injection. Power analysis demonstrates the need to randomize 250 children (125 with BTX-A, 125 with saline), allowing for attrition. Nine participating hospitals will contribute patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Spastic cerebral palsy;
- Bilateral lower extremity involvement;
- Spasticity present in the hamstrings;
- Flexed knee gait >15 degrees by observation (OGS);
- Age between 3 and 18 years old; (
- GMFCS Level I to Level IV; (
- Able to walk a minimum of 4 complete steps without resting with and without braces/shoes a minimum of 3 times;
- Able to follow simple commands;
- Cooperative with physicians and therapist;
- Able to tolerate application of equipment to the skin.
Exclusion Criteria:
- Rhizotomy surgery within the last 1 year;
- Lower extremity surgical procedures (soft tissue or bony) within the past 1 year;
- Currently implanted and operating Intrathecal Baclofen Pump (oral baclofen OK);
- Lower extremity BTX-A injections within the past 6 months;
- Multilevel BTX-A injections;
- Gait trainer reliance;
- Serial casting 3 months prior to or during study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
3DGA Kinematics
|
Passive Range of Motion
|
Spasticity Measurement with AShworth and Tardieu Scales
|
Muscle Strength and Control
|
Secondary Outcome Measures
Outcome Measure |
---|
6-Minute Walk Test
|
Gross Motor Function Measurement (GMFM)
|
Pediatric Outcomes Data Collection Instrument (PODCI)
|
Gillette Functional Assessment Questionnaire (GFAQ)
|
Goal Attainment Scale (GAS)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Philip E. Gates, MD, Shriners Hospitals for Children
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Brain Damage, Chronic
- Cerebral Palsy
- Paralysis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- 9199
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spastic Diplegic Cerebral Palsy
-
MTI UniversityEnrolling by invitationSpastic Diplegic Cerebral PalsyEgypt
-
Marmara UniversityUnknownCerebral Palsy, Spastic | Cerebral Palsy, Spastic, DiplegicTurkey
-
Riphah International UniversityRecruitingCerebral Palsy Spastic DiplegiaPakistan
-
Asir John SamuelUnknownHemiplegic Cerebral Palsy | Spastic Diplegic Cerebral Palsy
-
University of Southern CaliforniaCompletedSpastic Diplegic Cerebral PalsyUnited States
-
National Institute of Rehabilitation Medicine,...RecruitingCerebral Palsy, Spastic, DiplegicPakistan
-
Eunice Kennedy Shriver National Institute of Child...Shriners Hospitals for Children; University of DelawareUnknownSpastic Diplegic Cerebral PalsyUnited States
-
Riphah International UniversityRecruitingDiplegic Spastic Cerebral PalsyPakistan
-
Ekin AkpınarRecruiting
-
Universitaire Ziekenhuizen KU LeuvenCompleted
Clinical Trials on Botulinum Toxin A
-
AllerganTerminatedOveractive BladderSerbia, Turkey, Greece, Egypt, Lebanon, India
-
Walter Reed Army Medical CenterUnknown
-
YangHuiUnknown
-
Daewoong Pharmaceutical Co. LTD.Completed
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar RhytidesUnited States
-
AllerganCompletedOveractive BladderPortugal, South Africa, Netherlands, Canada, Singapore, Brazil, United States, Taiwan, Italy, United Kingdom, France, Spain
-
AllerganCompletedOveractive BladderUnited Kingdom, Belgium, New Zealand, France, Russian Federation, Czech Republic, United States, Germany, Austria, Poland, Slovakia, Ukraine, Canada, Australia
-
Mentor Worldwide, LLCSynteract, Inc.CompletedGlabellar Rhytides | Frown Lines Between the EyebrowsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic CarcinomaUnited States
-
University of MalayaCompleted